Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fomepizole oral - Horizon Pharma

Drug Profile

Fomepizole oral - Horizon Pharma

Alternative Names: 4-Methylpyrazole; 4-MP - Horizon Pharma; Convivia

Latest Information Update: 11 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Convivia
  • Developer Horizon Pharma
  • Class Antidotes; Pyrazoles; Small molecules
  • Mechanism of Action Alcohol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Metabolic disorders

Most Recent Events

  • 01 Sep 2015 Clinical development is ongoing in the USA
  • 12 Aug 2014 Fomepizole oral is still in phase II development for Metabolic disorders
  • 07 Jul 2014 Fomepizole oral - Raptor Therapeutics is available for licensing in Asia (excluding Taiwan) as of 07 Jul 2014. http://www.raptorpharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top